ClinicalTrials.gg

Cushing Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 123 studies for Cushing Syndrome across more than 10 countries. 42 are recruiting or about to start. 84 of them are mainly about Cushing Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
52
Recruiting
35
Status unknown
14
Terminated
7
Active, not recruiting
7
Not yet recruiting
6

Phase

Phase 2
25
Phase 3
9
Phase 4
6
Phase 1
6

Where

United States
58
Italy
21
France
16
Spain
10
Germany
10
Netherlands
9

Who develops what

Add Cushing Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 21 Jul 2027 est.Osilodrostat · RECORDATI GROUP · Phase 2 main aimNCT03708900 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome — primary endpoint: Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameters of osilodrostat up to Week 12 in children and adolescents 2 to less than 18 years of age with Cushing's Syndrome · 12 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cushing Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

0phase 3 studies under way
12studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger. 8 (23%) take children under 18. 0 (0%) are for women only and 1 (3%) for men only; 7 (20%) take healthy volunteers.

Recruiting studies that take each age, of 35
AgeWomenMen
106 (17%)6 (17%)
1832 (91%)33 (94%)
3032 (91%)33 (94%)
4031 (89%)32 (91%)
5031 (89%)32 (91%)
6531 (89%)32 (91%)
7528 (80%)29 (83%)
8517 (49%)17 (49%)

Across all 123 studies, recruiting or not: 28% stop at 75 or younger and 10% at 65; 20% take children; 1% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cushing Syndrome studies take

Of 31 observational studies under Cushing Syndrome, half reached primary completion within 95 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational95 mo85–… · 31 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 123. Browse all 123 → or search them.